Consistent with results of a study by Weiner et al. that demonstrated longer cancer-specific survival for patients with FOLH1-High tumors treated with androgen deprivation therapy,8 our study found prolonged treatment-related OS for patients with FOLH1-High tumors treated with ARPI, underscoring the relationship between PSMA/FOLH1 and AR signaling. The gene discussed is FOLH1; the disease is cancer.